Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Cash from Operations (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Cash from Operations for 15 consecutive years, with 17636000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 71.56% to 17636000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 60301000.0 through Dec 2025, down 54.54% year-over-year, with the annual reading at 42100000.0 for FY2025, 63.1% down from the prior year.
  • Cash from Operations hit 17636000.0 in Q4 2025 for Vistagen Therapeutics, down from 13800000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 4747000.0 in Q4 2023 to a low of 18800000.0 in Q2 2025.
  • Historically, Cash from Operations has averaged 11228815.0 across 5 years, with a median of 10574500.0 in 2024.
  • Biggest five-year swings in Cash from Operations: crashed 877.4% in 2021 and later soared 62.12% in 2023.
  • Year by year, Cash from Operations stood at 12045500.0 in 2021, then grew by 17.54% to 9933300.0 in 2022, then skyrocketed by 52.21% to 4747000.0 in 2023, then crashed by 116.56% to 10280000.0 in 2024, then crashed by 71.56% to 17636000.0 in 2025.
  • Business Quant data shows Cash from Operations for VTGN at 17636000.0 in Q4 2025, 13800000.0 in Q3 2025, and 18800000.0 in Q2 2025.